Key result
Valsartan was associated with a significantly lower risk of treatment discontinuation over 1 year compared to hydrochlorothiazide, amlodipine, and lisinopril in patients initiating antihypertensive monotherapy.
Why the study?
Does valsartan improve 1-year persistence and adherence compared to hydrochlorothiazide, amlodipine, or lisinopril in adults initiating antihypertensive monotherapy?
Population
60,685 adults initiating antihypertensive monotherapy, mean age 57.7, 48.2% male, United States. Key…
Comparison
Valsartan monotherapy (n=9,314) vs Hydrochlorothiazide, amlodipine, or lisinopril…
Design
Cohort
Follow-up
1 year
Authors
Loading...
Should not change prescribing based on observational data; leaves open whether RCTs confirm better persistence with valsartan.
Cohort (n=60,685)
Does valsartan improve 1-year persistence and adherence compared to hydrochlorothiazide, amlodipine, or lisinopril in adults initiating antihypertensive monotherapy?
Effect estimate: HR 1.53 (95% CI 1.47-1.61)
Absolute Event Rate: 44.2% vs 30.6%
p-value: p=<0.001
In a large US cohort, initiation of antihypertensive monotherapy with valsartan was associated with significantly better 1-year persistence and adherence compared to hydrochlorothiazide, amlodipine, or lisinopril.
Elliott et al. (2007) conducted a cohort in Hypertension (n=60,685). Hydrochlorothiazide vs. Valsartan was evaluated on Treatment discontinuation (HR 1.53, 95% CI 1.47-1.61, p=<0.001). Valsartan was associated with a significantly lower risk of treatment discontinuation over 1 year compared to hydrochlorothiazide, amlodipine, and lisinopril in patients initiating antihypertensive monotherapy.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: